The Lancet Haematology · 2019 · 72 citations · 23 references
PharmacyImmunologyPharmacotherapyImmuno-oncology PharmacotherapyImmunotherapyCancer ImmunotherapyChemotherapy In Hematologic MalignanciesCombination ImmunotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyImmune-related Adverse EventsB-cell Malignancy TherapyChronic Lymphocytic Leukemia TherapyFludarabine-based RegimensRituximab-based Therapy
23
Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text
Medicine, Hematology, Oncology +14
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Hematology, Oncology +12
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text
Medicine, Oncology, Pharmacotherapy +11
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +14